Drugs /

dexrazoxane

Back to Drugs List

Overview

NCI Definition [1]:
A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.

Clinical Trials

View Clinical Trials for dexrazoxane

Dexrazoxane has been investigated in 6 clinical trials, of which 6 are open and 0 are closed. Of the trials investigating dexrazoxane, 2 are phase 2 (2 open) and 4 are phase 3 (4 open).

BCR-ABL1 Fusion, FLT3 ITD, and PML-RARA Fusion are the most frequent biomarker inclusion criteria for dexrazoxane clinical trials.

Acute myeloid leukemia, acute lymphoblastic leukemia, and ganglioneuroblastoma are the most common diseases being investigated in dexrazoxane clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dexrazoxane
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dexrazoxane and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
4-[(2s)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione, dexrazoxane, (+)-(s)-4,4'-propylenedi-2,6-piperazinedione, razoxane (+)-form, dexrazoxano, razoxane, (s)-isomer, adr-529, dexrazoxane (substance), dexrazoxane (product), dexrazoxan, adr 529, (+)-(s)-4,4'-(1-methyl-1,2-ethanediyl)di(2,6-piperazinedione), icrf 187, icrf-187, (+)-1,2-bis(3,5-dioxo-1-piperazinyl)propane, icrf187, 2,6-piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (s)- (9ci), dexrazoxane, dextrorazoxane, adr529, 2,6-piperazinedione, 4,4'propylenedi-,(p)-(8ci), 2, 6-piperazinedione, 4,4'-propylenedi-, (p)- (8ci), 2,6-piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(s)-(9ci), dexrazoxanum, soluble icrf (l-isomer), dexrazoxane [chemical/ingredient]
NCIT ID [1]:
C1333
SNOMED ID [1]:
C-78032

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.